Take Control of Your Health Using Precision Medicine

Advanced genetic testing for the diagnosis,
monitoring & tailored treatment of
complex pancreatic diseases

A New Approach to Complex Disease Care

At Ariel, we believe every patient is unique and their care should be too.

That’s why we launched ADVANCE®, a new precision medicine platform that is transforming genetic and clinical data into new insights for the diagnosis and management complex health conditions.

About Pancreatitis

Are you experiencing symptoms of pancreatitis?

Here is what you need to know about the pancreas and pancreatic disease.

The Pancreas and Pancreatitis


Your pancreas creates digestive enzymes, which are made and released in an inactive, harmless form into the small intestine where they become activated and the process of digestion begins. The pancreas also regulates blood sugar in the body by releasing insulin and other hormones into the bloodstream.

Pancreatitis occurs when these enzymes become activated before leaving the pancreas, essentially beginning to digest the organ and causing inflammation, which leads to severe pain and other disabling problems. 

Forms of Pancreatitis


Pancreatitis can be a long-lasting condition where the health of the pancreas worsens over time. It is clinically categorized as either acute, recurrent acute, or chronic. 

Acute Pancreatitis (AP) is the initial form of the disease and it typically occurs suddenly and presents with severe abdominal pain. Symptoms normally require emergency medical treatment. The majority of patients will make a full recovery within a few days, but some patients develop further complications that may possibly lead to death if medical intervention is delayed. 

Recurrent Acute Pancreatitis (RAP) occurs when patients develop two or more of acute pancreatitis. Research has revealed up to 20% of acute pancreatitis becomes recurrent acute pancreatitis. During this time, it is recommended that patients get genetic testing done to help determine the underlying causes of their disease. By uncovering the underlying causes early on, care providers can help mitigate the progression of the disease and provide prompt medical intervention that may improve the patient’s disease trajectory.

Chronic Pancreatitis (CP) is the end stage form of the disease. It is a long-lasting condition where the health of the pancreas worsens over time. 20-40% of RAP progresses to CP. Patients with CP may have chronic pain, trouble digesting their food, and can develop diabetes. 
Pancreas in human body

Symptoms and Causes

Pancreatitis has several different causes. These can include your genetics, gallstones, high levels of fat in the blood and things you are exposed to from the environment, including medications, alcohol and smoking. Each different underlying cause may warrant a unique treatment.

Detection and Treatment

Diseases and related conditions of the pancreas can be hard to detect, and they have many possible risk factors and potential causes.  Because of this, traditional tests can be imprecise, making it difficult to quickly make an accurate diagnosis. 

Fortunately, advances in the understanding of pancreatic disease combined with new methods of genetic testing allow for earlier detection, diagnosis, and management plan of pancreatitis. This information helps your doctor develop a more effective course of treatment and may minimize the time spent bouncing between specialists and performing diagnostic testing.

Ariel Precision Medicine pancreatitis risk factors

Advanced Genetic Testing for Pancreatitis and Hypertriglyceridemia

PancreasDx® integrates your genetic data with your medical history and current symptoms to provide a comprehensive view of the factors that may be contributing to current conditions. Our reporting provides genetic and biological markers along with evidence-based guidelines that are individualized to each patient. Our genetic test results may also help you understand if there is an increased risk of pancreatitis in your relatives.

ArielDx® Lipids analyzes genetic susceptibility to hypertriglyceridemia, the presence of elevated triglycerides, a type of fat (lipid), in the blood. Hypertriglyceridemia increases an individual’s risk for developing cardiovascular disease, fatty liver disease, and pancreatitis. Severe hypertriglyceridemia is an established cause of pancreatitis, accounting for up to 10% of acute pancreatitis cases [1]. Variants in several genes can cause hereditary disorders of lipid metabolism or increase an individual’s risk for hypertriglyceridemia. Genetic testing may be helpful in determining the underlying cause of a patient’s disease and provide clinical guidance for targeted treatment. ArielDx Lipids may be appropriate for individuals with a personal or familial history of hypertriglyceridemia and pancreatitis. It is available as an add-on to PancreasDx during the ordering process.

Our goal is to minimize disease effects and maximize health and quality of life.

Patient specific

Who Should Get Tested?

For PancreasDx: Anyone who has had more than one attack of acute pancreatitis.

For ArielDx Lipids: Individuals with a personal or familial history of hypertriglyceridemia and pancreatitis.

In addition to traditional Mendelian variants, Ariel reports disease modifying and complex genetic variants.

Which Genes Are Tested?

 Our PancreasDx test analyzes genes that are related to pancreatitis and its complications, including PRSS1-2,  SPINK1, CFTR, CPA1, CASR, CEL, CLDN2, CTRC, GGT1, PRSS3, SBDS, SLC26A9 and UBR1.

Our ArielDx Lipids test analyzes genes that are related to hypertriglyceridemia  including APOA5, APOC2, FABP4, LPL, PPARG, GPIHBP1 and a region of interest in APOB exon 29.

What Kind of Technology is Used?

Ariel uses some of the highest quality next-generation sequencing on the market and our laboratory is CLIA-certified. 

Get Our Pancreatitis Patient Guide

PancreasDx is ordered by your doctor. Our guide will help you have a more informed discussion with your care team about whether genetic testing is the right fit for you.

Frequently Asked Questions

Anyone who has had an attack of acute pancreatitis, especially if they have had more than one attack. In addition, anyone who has signs or symptoms of pancreatic disease such as abdominal pain after eating, chronic diarrhea, abnormal findings on a CT or MRI scan, or an abnormal laboratory test linked to the pancreas. An early evaluation may possibly prevent lengthy and costly evaluations, delayed diagnosis and more complications.

PancreasDx analyzes genes that are related to pancreatitis and its complications, including PRSS1-2,  SPINK1, CFTR, CPA1, CASR, CEL, CLDN2, CTRC, GGT1, PRSS3, SBDS, SLC26A9 and UBR1.

If appropriate, your clinician can order an additional gene panel related to how your body handles fats and cholesterol in your blood that leads to an increased genetic risk of pancreatitis: 

  • ArielDx® Lipids is a panel of genes related to increased levels of fat in the blood. Some individuals have an inherited predisposition to these conditions, which is one of the causes of pancreatitis.
    • Genes tested include APOA5, APOB, APOC2, FABP4, LPL and PPARG

ArielDx® PGx is a next generation sequencing panel for pharmacogenomics that analyzes data from 11 genes related to drug metabolism (pharmacokinetics) and action (pharmacodynamics) that can be added-on to any PancreasDx order. Genes: CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, TPMT, UGT1A1, and VKORC1.

Ordering PancreasDx PancreasDx is ordered by your doctor or care provider. After the order is placed, you will receive an email invitation to register for access to Ariel’s patient portal. 

Patient Registration In the patient portal, you will be asked to complete your account registration and consent to testing and standard billing processes with your insurance. Once this is complete, you have the opportunity to answer some questions about your symptoms, your health history and whether anyone else in your family has similar symptoms. 

Billing and Insurance Once your account is registered, Ariel will contact your insurance to discuss your specific plan benefits and any potential out-of-pocket expenses. 

DNA Collection After registration, Ariel will ship a DNA collection kit to your home for sample collection. Our painless collection process collects cells using a large Q-tip (buccal swab), swiped across the inside of your cheek – each cell contains your DNA, which Ariel then uses for genetic analysis. Ariel includes a pre-paid padded envelope for you to return your sample directly through the mail.

Final Report Within 2-4 weeks of your sample arriving at our lab, your doctor will receive your PancreasDx report and be able to share it with you, in person or through the secure Ariel website. Log in to see your results and access tools for help, questions or for more information. 

Extra Help Ariel provides access to trained genetic counselors who can help you understand the test, the need for the test, and what it means for you and your family.

Ariel accepts all insurance plans.  As a new provider, we are not considered an in-network provider with all insurance plans.  While the organization continues to grow, Ariel will work towards establishing in-network status.  

The Ariel team follows the process below:

1.  When your physician orders PancreasDx®, you will receive a ‘Welcome’ email with a link to Ariel’s secure patient portal to register.  During registration, you will be asked to provide your insurance information.

2.  The Ariel team will contact your insurance provider to verify eligibility and benefits to assess potential out-of-pocket costs.  It is important to note that initial determinations from your insurance are subject to change, based on your clinical record and the discretion of the insurer.  

3.  Ariel’s billing team will contact you by phone to discuss benefits findings and any potential financial responsibility (i.e. co-pay, co-insurance, deductible).  Ariel works with your insurance directly through the claims and appeals process.  Our team will exhaust all efforts to obtain payment from your insurance plan to reduce or eliminate your financial responsibility for the service.  

For add-on panels, Ariel offers a direct-pay price of $100 (per test)* to make testing more accessible for you. You can choose to go through your insurance. However, you should be aware that most insurance plans do not cover add-on tests, like ArielDx PGx or ArielDx Lipids, and may result in out-of-pocket costs up to $1000. Patients will be prompted to select their payment method during the registration process.

Please note: Add-on testing cannot be completed until payment has been resolved.

*The patient-pay price cannot be offered after a claim has been submitted to the insurance.
Patients that select the direct pay option will pay the full $100 upfront. Ariel accepts checks and all major credit cards. Payments can be made through the Ariel Patient Portal, by phone at 844-692-7435 or by mail.

Checks should be made payable to: Ariel Precision Medicine

Mailing Address:
Ariel Precision Medicine
5750 Centre Ave, Suite 270
Pittsburgh, PA 15206
Ariel upholds the highest security measures to help ensure any personal information remains safe. We do not store cardholder data (CHD) in any cases.
Ariel is required by law to bill for applicable co-pays, co-insurance, and deductibles, as directed by your insurance benefit plan. Ariel will partner with you to implement the most appropriate payback plan based on financial need for a PancreasDx order.

Depending on your insurance plan, there may be situations where Ariel is considered an out-of-network provider and the payment for our test will be sent to you directly. You are legally responsbile for re-issuing that payment with a copy of the Explanation of Benefits, to Ariel for processing.
To ensure that PancreasDx is accessible to medically necessary patients, several options are available to support any patient out-of-pocket costs remaining after all billing efforts are exhausted with the insurance plan. Available options include payment plans, prompt pay discounts, and financial assistance based on individual need.
The direct-pay option for ArielDx PGx and ArielDx Lipids does not allow Ariel to submit claims to insurance providers or apply patient assistance programs-this is how we are able to keep the patient-pay price so low.
After your order is placed, you will receive an email invitation to register for access to Ariel’s patient portal.

In the patient portal, you will be asked to complete your account registration and consent to testing and standard billing processes with your insurance. Once this is complete, you have the opportunity to answer some questions about your symptoms, your health history and whether anyone else in your family has similar symptoms.
Ariel will send you an easy-to-use and non-invasive DNA collection kit to your home where you will collect your saliva sample and send it back to our laboratory for analysis.
Ariel will be able to use sequence data from the previously collected samples. In instances in which the analysis is not possible, Ariel will send a new collection kit to your home.

The security of your medical and genetic information is our priority. Ariel’s online portal meets or exceeds the highest regulations for health information privacy and security.

Furthermore, national and state laws exist to protect patient health information, which includes genetic information.

If this is a new order, the turnaround time for the test is approximately 4-6 weeks from the tie your sample is received in our laboratory.

If you have previously received PancreasDx testing, the turnaround time for add-on panel results is 2-3 weeks from the time Ariel receives the additional order.
Don’t hesitate to reach out to Ariel, Monday through Friday, 8 a.m. – 8 p.m. ET at (844) 692-7435 or via info@arielmedicine.com. General information on pancreatic diseases is available through Ariel’s Partner, the National Pancreas Foundation and www.pancreas.org.

Ariel Insights for Patients

1. de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018 Jun;6(5):649-655.